The Effect of Spironolactone on Control of Pulmonary Hypertension in Patients With Obstructive Pulmonary Disease Publisher



Emami M¹ ; Abdaresfahani M² ; Niknam K² ; Mehrabikoushki A³ Show Affiliations
Source: Journal of Isfahan Medical School Published:2019

Abstract

Background: This study aimed to determine the effect of spironolactone in control of pulmonary hypertension in patients with obstructive pulmonary disease (COPD) who admitted to Alzahra and Chamran hospitals in Isfahan, Iran, during the years 2017-2018. Methods: In a clinical trial study, 80 patients with COPD were selected and randomly divided in to two groups of 40. The first group received spironolactone at a dose of 25 mg, and the second group received routine treatment (without spironolactone). All patients underwent echocardiography and spirometry, and spirometry and electrocardiography parameters were compared between the two groups at the beginning and six months after the start of treatment. Findings: The mean pulmonary arterial pressure was 38.83 ± 6.9 and 39.65 ± 8.8 mmHg (P = 0.560), and 21.73 ± 6.12 and 24.5 ± 7.42 mmHg (P = 0.080), in control and intervention groups, before and 6 months after the treatment, respectively. The mean difference of pulmonary arterial pressure before and after the treatment was 25.4 ± 5.2 and 27.6 ± 5.2 mmHg in control and intervention groups, respectively, and no significant difference were seen between the two groups. Moreover, the improvements of spirometry and echocardiography indices were not statistically different between the two groups. Conclusion: Using spironolactone in patients with COPD has no significant effect on pulmonary hypertension, and spirometry and echocardiography indices, and more studies are needed in this regard. © 2019, Isfahan University of Medical Sciences(IUMS). All rights reserved.